Stocks
Intra-Cellular Therapies, Inc.ITCI
NASDAQHealthcareBiotechnology$131.87+0.00%
A biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, including schizophrenia and bipolar depression. Its lead product, Caplyta (lumateperone), is an antipsychotic approved in the U.S. and drives the company’s revenue growth while addi...
Market Cap: $14.0B52W Range: $64.09 – $131.98
Congressional Interest in Intra-Cellular Therapies, Inc. (ITCI)
3 members of Congress have disclosed 8 trades in Intra-Cellular Therapies, Inc. (ITCI), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 6 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
8
Unique Politicians
3
Buys
2
Sells
6
Who in Congress Is Trading ITCI?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-04-03 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-04-03 | Josh Gottheimer | sell | $1K – $15K |